Abstract:<h3 class="Heading">Background</h3><p class="Para">The bone marrow (BM) is a main risk organ during Lu-177-PSMA ligand therapy of metastasized castration-resistant prostate cancer (mCRPC) patients. So far, BM dosimetry relies on <em class="EmphasisTypeItalic">S</em> values, which are pre-computed for reference anatomies, simplified activity distributions, and a physiological BM distribution. However, mCRPC patients may show a considerable bone lesion load, which leads to a heterogeneous and patient-specific activity accumulation close to BM-bearing sites. Furthermore, the patient-specific BM distribution might be significantly altered in the presence of bone lesions. The aim was to perform BM absorbed dose calculations through Monte Carlo (MC) simulations and to investigate the potential value of image-based BM localization.</p><p class="Para">This study is based on 11 Lu-177-PSMA-617 therapy cycles of 10 patients (10 first cycles), who obtained a pre-therapeutic Ga-68-PSMA-11 PET/CT; quantitative Lu-177 SPECT acquisitions of the abdomen 24 (+CT), 48, and 72 h p.i.; and a Lu-177 whole-body planar acquisition at 24 h post-therapy. Patient-specific 3D volumes of interest were segmented from the Ga-68-PSMA-11 PET/CT, filled with activity information from the Lu-177 data, and imported into the FLUKA MC code together with the patient CT. MC simulations of the BM absorbed dose were performed assuming a physiological BM distribution according to the ICRP 110 reference male (MC1) or a displacement of active BM from the direct location of bone lesions (MC2). Results were compared with those from <em class="EmphasisTypeItalic">S</em> values (SMIRD). BM absorbed doses were correlated with the decrease of lymphocytes, total white blood cells, hemoglobin level, and platelets. For two patients, an additional pre-therapeutic Tc-99m-anti-granulocyte antibody SPECT/CT was performed for BM localization.</p><h3 class="Heading">Results</h3><p class="Para">Median BM absorbed doses were 130, 37, and 11 mGy/GBq for MC1, MC2, and SMIRD, respectively. Significant strong correlation with the decrease of platelet counts was found, with highest correlation for MC2 (MC1: <em class="EmphasisTypeItalic">r</em> = − 0.63, <em class="EmphasisTypeItalic">p</em> = 0.04; MC2: r = − 0.71, <em class="EmphasisTypeItalic">p</em> = 0.01; SMIRD: <em class="EmphasisTypeItalic">r</em> = − 0.62, <em class="EmphasisTypeItalic">p</em> = 0.04). For both investigated patients, BM localization via Tc-99m-anti-granulocyte antibody SPECT/CT indicated a displacement of active BM from the direct location of lesions similar to model MC2 and led to a reduction in the BM absorbed dose of 40 and 41% compared to MC1.</p><h3 class="Heading">Conclusion</h3><p class="Para">Higher BM absorbed doses were observed for MC-based models; however, for MC2, all absorbed doses were still below 2 Gy. MC1 resulted in critical values for some patients, but is suspected to yield strongly exaggerated absorbed doses by neglecting bone marrow displacement. Image-based BM localization might be beneficial, and future studies are recommended to support an improvement for the prediction of hematoxicities.</p>

Radiation levels outside a patient undergoing 177Lu-PSMA radioligand therapy

Radiation Safety Assessment in Prostate Cancer Treatment: A Predictive Approach for I-125 Brachytherapy

Evaluation Of The Dosimetric Impact Of Interfractional Anatomical Variations On Prostate Proton Therapy Using Daily In-Room Ct Images

Technical note: Investigating the suitability of existing facilities for a new Lu-177 prostate-specific membrane antigen therapy program

3D Monte Carlo bone marrow dosimetry for Lu-177-PSMA therapy with guidance of non-invasive 3D localization of active bone marrow via Tc-99m-anti-granulocyte antibody SPECT/CT

Dosimetry of [177Lu]Lu-PSMA-Targeted Radiopharmaceutical Therapies in Patients with Prostate Cancer: A Comparative Systematic Review and Metaanalysis

Estimation of relative biological effectiveness of 225Ac compared to 177Lu during [225Ac]Ac-PSMA and [177Lu]Lu-PSMA radiopharmaceutical therapy using TOPAS/TOPAS-nBio/MEDRAS

Bone marrow dosimetry in low volume mHSPC patients receiving Lu-177-PSMA therapy using SPECT/CT

Evaluation of Radiation Dose to Anthropomorphic Paediatric Models from Positron-Emitting Labelled Tracers.

Comparison of Measured and Calculated Dose Rates Near Nuclear Medicine Patients

Radiation Protection and Occupational Exposure on 68Ga-PSMA-11-Based Cerenkov Luminescence Imaging Procedures in Robot-Assisted Prostatectomy

Single-Time-Point Renal Dosimetry Using Nonlinear Mixed-Effects Modeling and Population-Based Model Selection in [ 177 Lu]Lu-PSMA-617 Therapy

Calculated Organ Equivalent Doses for Individuals in a Sitting Posture above a Contaminated Ground and a PET Imaging Room

Internal Dosimetry Assessment of Beta, Beta/Auger, and Alpha Decaying Radionuclidesin Targeted Radionuclide Therapy for Prostate Cancer: A Simulation Study

Therapeutic efficacy of the radiopharmaceutical [Lu-177]Lu-PSMA I&T.Preclinical study

Study on the Radiation Dose Distribution of Abdominal CT Scans Based on Dose Simulation Humans

Simulation, Visualization and Dosimetric Validation of Scatter Radiation Distribution under Fluoroscopy Settings

Intra-therapeutic dosimetry of [177Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome

Spatiotemporal modeling of radiopharmaceutical transport in solid tumors: Application to 177 Lu-PSMA therapy of prostate cancer

SU-GG-T-347: Methods to Calculate Organ Doses Due to Scattered Radiation From External Beam Radiation Treatment Using Various Patient Phantoms and Monte Carlo Simulations

Personalized dosimetry assessment of [177Lu]Lu-PSMA-617 radioligand therapy in the management of metastatic castration-resistant prostate cancer